Very Early Mobilization After Stroke Fast-Tracks Return to Walking
Further Results From the Phase II AVERT Randomized Controlled Trial

Toby B. Cumming, PhD; Amanda G. Thrift, PhD; Janice M. Collier, PhD; Leonid Churilov, PhD; Helen M. Dewey, PhD; Geoffrey A. Donnan, MD; Julie Bernhardt, PhD

Background and Purpose—Regaining functional independence is an important goal for people who have experienced stroke. We hypothesized that introducing earlier and more intensive out-of-bed activity after stroke would reduce time to unassisted walking and improve independence in activities of daily living.

Methods—A Very Early Rehabilitation Trial (AVERT) was a phase II randomized controlled trial. Patients with confirmed stroke (infarct or hemorrhage) admitted <24 hours after stroke and who met physiological safety criteria were eligible. Patients randomized to the very early and intensive mobilization group were mobilized within 24 hours of stroke and at regular intervals thereafter. Control patients received standard stroke unit care. The primary outcome for this analysis was the number of days required to return to walking 50 m unassisted. Secondary outcomes were the Barthel Index and Rivermead Motor Assessment at 3 and 12 months after stroke.

Results—Seventy-one stroke patients with a mean age of 74.7 years were recruited from 2 hospitals. Adjusted Cox regression indicated that very early and intensive mobilization group patients returned to walking significantly faster than did standard stroke unit care controls ($P=0.032$; median 3.5 vs 7.0 days). Multivariable regression revealed that exposure to very early and intensive mobilization was independently associated with good functional outcome on the Barthel Index at 3 months ($P=0.008$) and on the Rivermead Motor Assessment at 3 ($P=0.050$) and 12 ($P=0.024$) months.

Conclusions—Earlier and more intensive mobilization after stroke may fast-track return to unassisted walking and improve functional recovery.

Clinical Trial Registration—This trial was not registered because enrollment began before July 2005.
(Stroke. 2011;42:153-158.)

Key Words: acute care ■ cerebrovascular disease ■ functional recovery ■ randomized controlled trials ■ rehabilitation

As a consequence of focal brain ischemia or hemorrhage, stroke can have both immediate and ongoing physical effects. Within 12 months of stroke, one third of stroke patients will die and another third are left with disability, restricted in performing simple activities of daily living (ADLs) and requiring some kind of assistance. Of all recovery goals, improved walking function is the one most often expressed by patients with stroke.

The rate of physical recovery is not linear; the most rapid improvement occurs within the first 6 months after stroke. In a study of 976 acute stroke patients, Wade and Hewer reported some recovery between 3 weeks and 6 months in almost all patients, and by 6 months, approximately half of the survivors had regained functional independence. In another large study, approximately two thirds of patients were unable to walk without assistance in the first week after stroke. Among those initially unable to walk, 95% of patients recovered within the first 3 months, with leg paresis strongly associated with the rate of recovery. In addition to stroke severity, increasing age and diabetes are factors that have been associated with a lower rate and extent of functional recovery after stroke.

Both the speed and extent of recovery are important to survivors of stroke, yet research examining the efficacy of interventions on recovery milestones is limited. A meta-analysis of studies that included augmented exercise intensity revealed a positive effect on ADLs in the first 6 months after stroke. Treatment in a dedicated stroke unit has been associated with more rapid and greater recovery of independence in ADLs when compared with patients treated on a
general medical ward. Walking recovery was not specifically measured in this study, but a post hoc analysis indicated that a shorter time to start of mobilization after stroke onset was the most important factor associated with discharge to home. Given the general lack of physical activity in the first weeks after stroke, we believed that there was an opportunity to introduce earlier and more frequent mobilization. The safety and feasibility of this intervention were the primary outcomes tested as part of a phase II clinical trial comparing a very early and intense mobilization protocol (VEM) with standard stroke unit care (SC). In the current article, we report the outcomes associated with recovery of walking and independence in ADLs. We hypothesized that patients in the VEM group would walk unassisted sooner than SC controls. We also hypothesized that VEM patients would achieve better functional independence (as measured by the Barthel Index and Rivermead Motor Assessment) than SC controls at 3 and 12 months after stroke.

Methods

Design

A Very Early Rehabilitation Trial (AVERT) phase II was a prospective randomized controlled trial with concealed allocation, blinded assessment of outcomes, and intention-to-treat analysis. The setting was the acute stroke units of 2 large hospitals in Melbourne, Australia. Ethics approval was obtained. The methods have been reported in detail elsewhere and are summarized in the subsequent paragraphs.

Population

Patients were included if they (1) were ≥18 years; (2) satisfied physiological limits (systolic blood pressure 120 to 220 mm Hg, heart rate 40 to 100 bpm, oxygen saturation >92%, and temperature <38.5°C); and (3) could be randomized within 24 hours of symptom onset of a first or recurrent stroke. Patients were excluded if they had a premorbid modified Rankin Scale (mRS) score >3 (indicating disability), deterioration within the first hour of admission to the stroke unit or direct admission to intensive care, concurrent progressive neurological disorder, acute coronary syndrome, severe heart failure, lower-limb fracture that prevented mobilization, or required palliative care.

Procedure

When discussing informed consent, patients were told that they would be given 1 of 2 different types of rehabilitation. Computer-generated, blocked randomization procedures and concealment with opaque envelopes were used to allocate patients to either the VEM or SC group. Randomization was stratified by hospital site and stroke severity on the National Institutes of Health Stroke Scale (NIHSS) to reduce the likelihood of severity imbalance between groups.

Intervention

Both VEM and SC groups received standard care from ward therapists and nursing staff in the stroke units. Patients randomized to the VEM group began mobilizing as soon as practical after randomization, with the goal of first mobilization within 24 hours of stroke onset. The VEM group also received additional interventions, with the aim of assisting patients to be upright and out of bed at least twice per day, thereby doubling the standard care “mobilization dose” previously identified. VEM was delivered by a trained nurse and physiotherapist team for the first 14 days after stroke or until discharge from the acute stroke unit (whichever was sooner). The type and dose of therapy for both groups were recorded on personal digital assistants. Occupational health and safety procedures for manual handling of patients were maintained. Blood pressure, heart rate, oxygen saturation, and temperature were monitored before the first 3 mobilizations of VEM patients. “Contamination” of standard care was monitored throughout the study.

Baseline Assessment

Baseline assessment included age, sex, stroke type according to the Oxfordshire stroke classification, stroke severity on the NIHSS, diabetes status as well as other stroke risk factors, prestroke living arrangements, and prestroke functional level on the mRS. The mobility scale for acute stroke was used to establish baseline restrictions in a patient’s ability to move in bed, sit up, and walk 10 m, and information from this scale was used to guide the VEM intervention level.

Outcome Measures

Assessments by the blinded assessor took place at 7 and 14 days and 3, 6, and 12 months after stroke. For this data analysis, the main outcome of interest was time to walking 50 m. This was defined as the number of days from stroke onset until the patient could first walk 50 m without human assistance, a distance used in the Functional Independence Measure walking item and commonly marked out within hospital departments. To remove the subjectivity associated with both the need for supervision (Functional Independence Measure score 5) and walking aid (Functional Independence Measure score 6), we defined walking as “walking unassisted by human help (gait aid allowed) for a continuous distance of 50 meters.” Physiotherapists were responsible for completion of the 50-m walk.

The other outcome measures were the Barthel Index and Rivermead Motor Assessment, both assessed at 3 and 12 months after stroke. The Barthel Index, a valid and reliable measure of ADLs in stroke research, was used to assess independence in 10 everyday activities. The total score sums to 20, and higher scores reflect better performance. As per common practice with the Barthel Index, patients were classified as either independent (score=20) or dependent (score=0 to 19) in ADLs. The Rivermead Motor Assessment gross function scale of 13 items was used to examine motor activity and has established reliability in stroke. It includes easy and difficult items, with the first item testing unsupported sitting, and other items testing ability to transfer, walk indoors, walk outdoors, run, and hop on the spot. The best performance of 3 trials on each item was scored, with a score of 0 indicating that the patient was unable to perform any of the activities independently and a score of 13 indicating independence with all activities. Patients were classified as either impaired (score=0 to 9) or not impaired (score=10 to 13) in motor activity, a cutoff chosen to align with the clinically meaningful ability to walk outside the home (community ambulation).

Statistical Analysis

A sample of 70 patients was deemed sufficient to allow examination of the primary safety outcome of the study (death) at 3 months after stroke. Although the study was not powered to detect differences in physical outcomes reported in this article, an important part of feasibility testing includes evaluation of performance and utility of the outcome measures used.

Because one third of stroke patients die in the first 12 months, analyses must deal with missing data due to deaths. Furthermore, when inclusion criteria are broad, as in this trial, stroke symptoms can vary markedly, with the result that some patients will fail to achieve any score on a given test, particularly those related to higher levels of activity. Excluding patients who died or who failed to achieve a score on a test would bias results, and imputing data values for these subjects requires guesswork. In this study, all patients who died were assigned a score of 0 on the Barthel and Rivermead scales for all subsequent time points. A score of 0 was deemed likely to reflect their status had they still been alive, given that people who die in the first year after stroke are more likely to have had a severe stroke (and would be expected to have a very low score on these measures). Patients alive at the time of assessment with missing data
were not included in analyses. Multivariable analyses were used to account for demographic and stroke-related factors known to influence walking and functional independence (age, stroke severity, and diabetes) and other factors that may also impact these outcomes (sex and premorbid disability).

Days to Walking
The number of days between stroke onset and a 50-m unassisted walk was recorded. A Cox regression was performed with adjustment for important prognostic variables (age, sex, NIHSS, premorbid mRS and diabetes).

Barthel Index
Mann-Whitney U tests were used to assess between-group differences in Barthel score. Barthel data were then used to classify patients as either independent or dependent in ADLs, and Fisher’s exact tests were used to detect group differences. Multivariable logistic-regression analyses, with the Barthel Index as the binary outcome measure, were then performed to determine the effect of group (VEM or SC), age, sex, NIHSS, premorbid mRS and diabetes on independence in ADLs.

Rivermead Motor Assessment
Between-group differences in Rivermead scores were analyzed by Mann-Whitney U tests. Rivermead data were then used to classify patients as either impaired or not impaired in motor activity, and Fisher’s exact tests were used to detect group differences. Multivariable logistic-regression analyses were then performed on the binary Rivermead data in the same way as described for the Barthel Index.

### Results
Seventy-one patients were recruited from 2004 to 2006: 60 from the Austin Hospital and 11 from St. Vincent’s Hospital (Figure 1). Baseline characteristics between groups were similar (Table 1). Notably, 58% of the sample had moderate or severe stroke. Median time to mobilization was shorter in VEM (18 hours) than in SC (31 hours), and the median total dose of mobilization was greater for VEM (167 minutes) than for SC (69 minutes).

Three surviving patients had missing data, but inspection of their characteristics showed that any systematic bias was unlikely. They were not all from one group (2 VEM, 1 SC), they had a range of ages (58, 82, and 86 years), and they did not have severe stroke (NIHSS of 1, 5 and 7).

#### Table 1. Baseline Characteristics of Recruited Patients

<table>
<thead>
<tr>
<th>Patient details</th>
<th>SC n=33</th>
<th>VEM n=38</th>
<th>Total N=71</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, mean (SD), y</td>
<td>74.9 (9.8)</td>
<td>74.6 (14.6)</td>
<td>74.7 (12.5)</td>
</tr>
<tr>
<td>Female</td>
<td>17 (53)</td>
<td>16 (42)</td>
<td>33 (46)</td>
</tr>
<tr>
<td>Stroke details</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Left-sided lesion</td>
<td>14 (42)</td>
<td>22 (58)</td>
<td>36 (51)</td>
</tr>
<tr>
<td>NIHSS score</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mild (1–7)</td>
<td>15 (46)</td>
<td>15 (39)</td>
<td>30 (42)</td>
</tr>
<tr>
<td>Moderate (8–16)</td>
<td>11 (33)</td>
<td>13 (34)</td>
<td>24 (34)</td>
</tr>
<tr>
<td>Severe (&gt;16)</td>
<td>7 (21)</td>
<td>10 (26)</td>
<td>17 (24)</td>
</tr>
<tr>
<td>Oxfordshire Stroke Classification</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TACI</td>
<td>6 (18)</td>
<td>10 (26)</td>
<td>16 (23)</td>
</tr>
<tr>
<td>PACI</td>
<td>10 (30)</td>
<td>13 (34)</td>
<td>23 (32)</td>
</tr>
<tr>
<td>POCI</td>
<td>5 (15)</td>
<td>7 (18)</td>
<td>12 (17)</td>
</tr>
<tr>
<td>LACI</td>
<td>6 (18)</td>
<td>5 (13)</td>
<td>11 (15)</td>
</tr>
<tr>
<td>ICH</td>
<td>6 (18)</td>
<td>3 (8)</td>
<td>9 (13)</td>
</tr>
<tr>
<td>Prior history of stroke</td>
<td>7 (21)</td>
<td>11 (29)</td>
<td>18 (25)</td>
</tr>
<tr>
<td>Stroke risk factors</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>25 (76)</td>
<td>25 (66)</td>
<td>50 (70)</td>
</tr>
<tr>
<td>Ischemic heart disease</td>
<td>13 (39)</td>
<td>7 (18)</td>
<td>20 (28)</td>
</tr>
<tr>
<td>Angina</td>
<td>9 (27)</td>
<td>5 (13)</td>
<td>14 (20)</td>
</tr>
<tr>
<td>Hypercholesterolemia</td>
<td>11 (33)</td>
<td>8 (21)</td>
<td>19 (27)</td>
</tr>
<tr>
<td>Diabetes</td>
<td>4 (12)</td>
<td>11 (29)</td>
<td>15 (21)</td>
</tr>
<tr>
<td>Smoking</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Never smoked</td>
<td>15 (45)</td>
<td>15 (47)</td>
<td>30 (46)</td>
</tr>
<tr>
<td>Smoker†</td>
<td>6 (18)</td>
<td>7 (22)</td>
<td>13 (20)</td>
</tr>
<tr>
<td>Ex-smoker†</td>
<td>12 (36)</td>
<td>10 (31)</td>
<td>22 (34)</td>
</tr>
<tr>
<td>Unknown</td>
<td>0 (0)</td>
<td>6 (16)</td>
<td>6 (8)</td>
</tr>
<tr>
<td>Factors limiting mobilization</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Respiratory‡</td>
<td>5 (15)</td>
<td>4 (11)</td>
<td>9 (13)</td>
</tr>
<tr>
<td>Lower limb§</td>
<td>7 (21)</td>
<td>11 (29)</td>
<td>18 (25)</td>
</tr>
<tr>
<td>Premorbid history</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Premorbid mRS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>20 (61)</td>
<td>18 (47)</td>
<td>38 (54)</td>
</tr>
<tr>
<td>1</td>
<td>8 (24)</td>
<td>6 (16)</td>
<td>14 (20)</td>
</tr>
<tr>
<td>2</td>
<td>2 (6)</td>
<td>8 (21)</td>
<td>10 (14)</td>
</tr>
<tr>
<td>3</td>
<td>3 (9)</td>
<td>6 (16)</td>
<td>9 (13)</td>
</tr>
<tr>
<td>Living arrangement on admission</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Home , alone</td>
<td>7 (21)</td>
<td>4 (11)</td>
<td>11 (15)</td>
</tr>
<tr>
<td>Home, with someone</td>
<td>25 (76)</td>
<td>30 (79)</td>
<td>55 (78)</td>
</tr>
<tr>
<td>Hostel</td>
<td>1 (3)</td>
<td>4 (11)</td>
<td>5 (7)</td>
</tr>
</tbody>
</table>

*No. (percent) unless otherwise indicated.

TACI indicates total anterior circulation infarct; PACI, partial anterior circulation infarct; POCI, posterior circulation infarct; LACI, lacunar infarct; and ICH, intracerebral hemorrhage.

†Smoker = current smoker or who quit within the last 2 years. Ex-smoker=quit > 2 years ago.

‡Respiratory limiting factors included emphysema and chronic obstructive airway disease.

§Lower-limb limiting factors included lower-limb arthritis and lower-limb joint replacement.
Days to Walking
On admission, 86% of patients could not walk or required hands-on assistance to walk short distances (mobility scale for acute stroke gait score 1 to 4; VEM n=34, SC n=27). Only 14% of patients were rated as able to walk with supervision (VEM n=4, SC n=6). Median days taken to return to walking 50 m was 3.5 (interquartile range [IQR]=1.5 to 14.0) in the VEM group and 7.0 (IQR=2.0 to 20.0) in the SC group. At 2 weeks after stroke (the end of the intervention period) among surviving patients, 67% (22 of 33) of the VEM group had returned to unassisted walking compared with 50% (16 of 32) of the SC group. Results of the Cox regression analysis, with adjustment for potentially confounding variables, demonstrated a significant impact of the intervention on time to walking ($P=0.032$; Table 2). The log-minus-log function indicated that the assumption of proportionality was met. Patients in the VEM group returned to independent walking sooner than did SC patients, as shown in the adjusted survival curves (Figure 2).Earlier return to walking after stroke was also independently associated with less severe stroke (NIHSS), younger age, and absence of diabetes (Table 2).

Barthel Index
Proxy respondents provided answers for 21% of 3-month survivors and 17% of 12-month survivors (primarily due to the patient having communication difficulties). The distribution of Barthel scores was bimodal, with most patients having a communication difficulties). The distribution of Barthel Index at 3 months compared with 56% (18 of 32) of SC patients ($P=0.136$). Scores on the Barthel Index at 12 months were not significantly different between groups, with 39% of patients having a good outcome in both VEM (median=18.0, IQR=0.0 to 20.0) and SC (median=18.0, IQR=7.0 to 20.0) groups. In the multiple regression analysis, having a good outcome on the Barthel Index at 3 months was independently associated with exposure to VEM, less severe stroke on admission (NIHSS), and younger age. Having a good Barthel outcome at 12 months was independently associated with less severe stroke, younger age, male sex, and absence of diabetes, but the effect of exposure to VEM was no longer apparent (Table 3). Results were similar when the analyses were restricted to survivors only (data not shown).

Rivermead Motor Assessment
Scores on the Rivermead assessment at 3 months were similar in VEM (median=10.0, IQR=0.5 to 11.0) and SC (median=10.0, IQR=3.0 to 11.0) groups ($P=0.883$). In VEM, 62% (23 of 37) of patients had a good Rivermead outcome at 3 months compared with 56% (18 of 32) of SC patients ($P=0.633$). Scores on the Rivermead at 12 months were not significantly different between groups, with 53% of VEM patients having a good outcome (median=10.0, IQR=0.0 to 11.0) compared with 45% of SC patients (median=9.0, IQR=1.0 to 11.0). In multiple regression, having a good Rivermead outcome was independently associated with exposure to VEM, less severe stroke (NIHSS), and younger age, at both 3 and 12 months (Table 4). Results were similar when the analyses were restricted to survivors only, although age was no longer associated with good outcome (data not shown).

Discussion
The most important finding was that stroke patients who received VEM in addition to standard stroke unit care were
able to walk unassisted sooner than patients who received standard stroke unit care alone. One major clinical implication of this result is that walking sooner increases the likelihood of milder stroke patients being discharged from acute care directly to home rather than to a rehabilitation facility. Our data support this possibility: despite the VEM group having more patients with moderate to severe strokes than the SC group, length of stay in the acute care hospital was shorter for VEM than for SC patients (median 6 vs 7 days), and they were more likely to be discharged directly to home (32% vs 24%). The study by Indredavik et al,12 in which a shorter time to start of mobilization was the most important factor associated with discharge to home, also supports this idea. A potential explanation for the faster return to walking is that motor performance was improved by earlier and more frequent out-of-bed experiences. It is also possible that the increased physical activity served to minimize the muscle loss and deterioration in cardiorespiratory function associated with bed rest25 and thus made walking 50 m unassisted less demanding. A further possibility is that self-efficacy was enhanced; that is, the early sessions of mobilization constituted “mastery experiences” that gave the patient increased confidence in his or her own ability to walk.26,27

Our hypothesis that patients exposed to the intervention would have better functional independence than controls at 3 months was supported by the findings from the multiple regression analyses, whereby more VEM patients were independent in ADLs (Barthel Index) and motor function (Rivermead Motor Assessment) than SC patients. Taken together with the walking findings, this indicates that providing earlier and more intensive mobilization after stroke can accelerate the recovery of meaningful physical outcomes. At 12 months, VEM patients remained more independent in motor function than controls, but there was no significant group difference for independence in ADLs. Previous studies have demonstrated that in the longer term, stroke patients who have not received augmented training eventually achieve the same level of function as those who have.3 It should be noted that our study was not powered to detect changes in functional outcomes in response to the addition of an early mobilization program. As Tables 3 and 4 show, the confidence intervals around the effect of intervention group were wide, and whether these promising findings are confirmed in the larger phase III study (currently underway)28 remains to be seen.

Age and stroke severity strongly influenced recovery as measured by the Barthel and Rivermead at both 3 and 12 months after stroke, with younger patients and those with less severe stroke achieving greater functional independence. This is consistent with previous findings.7–9 The negative influence of diabetes on functional independence found with walking recovery and the Barthel Index at 12 months also has precedent.8,10

As outcome measures in a research context, the Barthel Index and Rivermead Motor Assessment are not perfect. They are brief, ordinal scales that produce data that are not normally distributed, with ceiling effects a particular issue for the Barthel. It is possible that differences in independence in ADLs between groups were present at 12 months in the current study but that a ceiling effect in the Barthel data precluded their detection. More than half of the surviving patients were at ceiling on the Barthel scale (20/20) at 12 months after stroke. The weakness of the Barthel in discriminating between people at moderate versus high levels of function has been well documented.29 Furthermore, neither the Barthel nor the Rivermead measure incorporates death in its scale (as the mRS does). In contrast to many published rehabilitation studies, deaths were not excluded from our analyses of physical outcomes. Rather, we assigned patients who had died a score of 0 for both the Barthel and Rivermead measures to prevent overestimation of recovery in this group. In light of these considerations, it was necessary to dichotomize the Barthel and Rivermead data for analyses so that statistical assumptions were not violated. The consequence of the dichotomization approach is a reduction in sensitivity of the measures. These assessments, however, are widely used and readily understood in rehabilitation settings (both clinical and research), and this explains their choice as outcome measures here.

Any intervention that accelerates functional recovery is important both to stroke survivors and clinicians. This study provides novel evidence that earlier and more intensive mobilization in the acute phase of stroke can accelerate recovery of walking and functional independence. The findings from AVERT phase III will provide greater certainty regarding the efficacy of VEM in the recovery of physical independence after stroke.

**Acknowledgments**

We thank all of the stroke survivors and their caregivers who participated in this study. We gratefully acknowledge the support of the clinical staff at the Austin Hospital and St. Vincent’s Hospital and all those involved at the National Stroke Research Institute.

**Sources of Funding**

This trial was supported by grants from the National Heart Foundation of Australia (grant number G 04M 1571), Affinity Health, and an equipment grant from the Austin Health Medical Research Fund. Dr Bernhardt was supported by a National Health and Medical Research Council (Australia) fellowship (157305).

---

**Table 4. Multivariable Binary Logistic Regressions, With Independence in Motor Function (Rivermead=10–13 vs Rivermead=0–9) at 3 and 12 Months as the Outcome Variable**

<table>
<thead>
<tr>
<th></th>
<th>3 Months (N=69)*</th>
<th>12 Months (N=69)†</th>
</tr>
</thead>
<tbody>
<tr>
<td>OR</td>
<td>95% CI</td>
<td>P</td>
</tr>
<tr>
<td></td>
<td>95% CI</td>
<td>P</td>
</tr>
<tr>
<td>VEM</td>
<td>8.21 1.00 67.64 0.050</td>
<td>9.62 1.34 68.83 0.024</td>
</tr>
<tr>
<td>Age</td>
<td>0.90 0.81 1.00 0.046</td>
<td>0.88 0.78 0.98 0.024</td>
</tr>
<tr>
<td>Sex</td>
<td>1.52 0.27 8.67 0.635</td>
<td>4.44 0.83 23.65 0.081</td>
</tr>
<tr>
<td>NIHSS</td>
<td>0.66 0.54 0.82 &lt;0.001</td>
<td>0.71 0.59 0.85 &lt;0.001</td>
</tr>
<tr>
<td>Premorbid</td>
<td>0.66 0.27 1.62 0.361</td>
<td>0.44 0.18 1.05 0.065</td>
</tr>
<tr>
<td>Diabetes</td>
<td>0.71 0.08 6.38 0.761</td>
<td>0.13 0.02 1.07 0.058</td>
</tr>
</tbody>
</table>

OR indicates odds ratio.

*Eleven patients who died were included by assigning a Rivermead score of 0; 2 survivors had missing data.
†Seventeen patients who died were included by assigning a Rivermead score of 0; 2 survivors had missing data.
Disclosures

None.

References


Very Early Mobilization After Stroke Fast-Tracks Return to Walking: Further Results From the Phase II AVERT Randomized Controlled Trial
Toby B. Cumming, Amanda G. Thrift, Janice M. Collier, Leonid Churilov, Helen M. Dewey, Geoffrey A. Donnan and Julie Bernhardt

*Stroke.* 2011;42:153-158; originally published online December 9, 2010;
doi: 10.1161/STROKEAHA.110.594598

*Stroke* is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2010 American Heart Association, Inc. All rights reserved.
Print ISSN: 0039-2499. Online ISSN: 1524-4628

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://stroke.ahajournals.org/content/42/1/153

Data Supplement (unedited) at:
http://stroke.ahajournals.org/content/suppl/2012/02/28/STROKEAHA.110.594598.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Stroke* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to *Stroke* is online at:
http://stroke.ahajournals.org//subscriptions/
卒中后超早期活动：重返行走的快速途径
随机对照试验超早期康复试验 II(A VERT II) 的进一步结果

**Original Contributions**

**Very Early Mobilization After Stroke Fast-Tracks Return to Walking**

**Further Results From the Phase II A VERT Randomized Controlled Trial**

Toby B. Cumming, PhD; Amanda G. Thrift, PhD; Janice M. Collier, PhD; Leonid Churilov, PhD; Helen M. Dewey, PhD; Geoffrey A. Donnan, MD; Julie Bernhardt, PhD

**背景与目的:** 重新获得功能上的独立是卒中患者的重要目标。我们假设卒中后更早和更密集的下床活动将会缩短恢复至独立行走的时间并改善日常生活活动的独立性。

**方法:** 超早期康复试验 (A Very Early Rehabilitation Trial, A VERT) 是一项 II 期随机对照试验。入组的是 24 小时内入院、满足生理安全标准的确诊卒中 (梗死或出血) 的患者。随机到超早期、密集活动组的患者在卒中后 24 小时内开始进行开始活动，此后定期活动。对照组患者接受标准卒中单元护理。主要终点指标是恢复至独立行走 50 米所需的天数。次要终点指标包括卒中后 3 个月时的 Barthel 指数和 Rivermead 运动功能评分。

**结果:** 共入组了来自两家医院的 71 例卒中患者, 平均年龄为 74.7 岁。校正的 Cox 回归分析显示, 超早期、密集活动组患者比标准卒中单元护理组恢复至行走的速度明显增快 ($P=0.032$; 中位时间分别为 3.5 天和 7.0 天)。多元回归分析显示, 超早期和密集活动与好的功能结局独立相关, 包括 3 个月时的 Barthel 指数 ($P=0.008$) 和 3 个月以及 12 个月时的 Rivermead 运动功能评分 ($P$ 值分别为 0.050 和 0.024)。

**结论:** 更早和更密集的卒中后活动可能是恢复独立行走的快速途径，并可能改善功能结局。

关键词: 急性治疗, 脑血管疾病, 功能性恢复, 随机对照试验, 康复

*(Stroke. 2011;42:153-158. 北京大学第一医院神经内科 邢海英 译 黄一宁 校)*

卒中由于可引起局灶性脑缺血或出血, 所以可以产生即刻的和进展的躯体影响。卒中后 12 个月内, 1/3 的患者死亡; 另外 1/3 的患者遗留有残疾，执行简单的日常生活活动 (activities of daily living, ADLs) 受限而需要一定的帮助 [1]。在所有的康复目标中，改善行走功能是最常被卒中患者提及的 [2]。

躯体功能恢复的速度不是线性的, 最快的改善发生在卒中后最初的 6 个月内 [3,4]。Wade 和 Hewer 在一项包括 976 例急性卒中患者的康复中报告, 几乎所有的患者在 3 周至 6 个月间都有一些恢复，至 6 个月时, 大约一半的幸存者获得了功能上的独立 [5]。在另一项大型研究中, 大约 2/3 的患者在卒中后第一周不能独立行走 [6], 在最初不能行走的患者中, 95% 在 3 个月内恢复, 遗留的下肢轻瘫的程度与恢复速率强相关。除了卒中严重程度 [7,8] 外，年龄的增加 [9,9]、糖尿病 [8,10] 与卒中后恢复速率慢和功能恢复程度相关。

恢复速度和程度对卒中存活患者都很重要, 然而观察干预措施在不同康复阶段的效力的研究有限。Meta 分析显示增加练习密度对卒中后最初 6 个月的日常生活活动能力 (ADLs) 有积极作用 [3]。与普通卒中治疗相比，专门的卒中单元治疗与更快和更大程度的 ADLs 独立性的恢复相关 [11]。在该研究中, 没有特别检查行走的恢复，事后分析 (post hoc) 分析显
示，卒中后短时间内开始活动是与出院直接回家相关的重要因素[12]。考虑到卒中后第一周常缺少躯体活动[13]，我们认为引入更早的、更密集的活动可以为卒中恢复提供良好的机会。在比较超早期、密集活动(very early and intense mobilization, VEM)和标准单元护理(standard stroke unit care, SC)的II期临床试验中，这项干预措施的安全性和有效性研究是主要结局指标[14]。本文中，我们将报告与行走恢复和ADLs独立性相关的结果。我们假定VEM组患者将比SC组患者更早的独立行走。我们也假定VEM组患者将比SC组患者在卒中后3个月和12个月获得更好的功能上的独立(通过Barthel指数和Rivermead运动功能评分来测量)。

方法

研究设计

II期超早期康复试验(A Very Early Rehabilitation Trial, A VERT)是一项前瞻性的随机对照临床试验，采用盲法分组、盲法结果评估和意向治疗分析。研究机构是澳大利亚墨尔本的两家大医院的急性卒中单元。获得了伦理批准。具体方法在其他文章中已详细报告[14]，将在下一段中简要总结。

研究人群

入组标准：(1)≥18岁；(2)满意的生理条件(收缩压120-220 mmHg，心率40-100 bpm，氧饱和度>92%，体温<38.5℃)；(3)首发或复发卒中，可以在症状发生24小时内随机化。排除标准：发病前改良Rankin评分(mRS)[15]>3(提示残疾)、进入卒中单元或监护室后第一小时内恶化、合并进展的神经系统疾病、急性冠脉综合征、严重的心力衰竭、影响活动的下肢骨折或者需要姑息治疗。

研究步骤

在讨论知情同意时，告知患者他将会获得两种不同的康复方式中的一种。采用计算机生成、封闭的随机化程序和密封的不透明信封，将患者分到VEM组或SC组。根据医院和卒中严重程度对随机化进行分层来减少组间严重程度的不平衡性，其中卒中严重程度根据NIHSS[16]来判定(轻度=0-7分，中度=8-16分，重度>16分)。

干预措施

VEM和SC组均在卒中单元中获得病房治疗师和护理者的标准护理。VEM组患者在随机化后，尽可能早的开始活动，来达到卒中后24小时内开始第一次活动的目标。VEM组患者也获得额外的干预，即将以前提到的标准护理“活动的剂量”加倍，以达到帮助患者每天站立和下床至少两次的目标。由经过训练的卒中单元的护士和物理治疗师组成的团队来完成VEM。时间为卒中后最初的14天或者直至出院(选择两者中比较早的)。两组患者的治疗类型和剂量均记录入掌上电脑中。人工辅助患者活动时，始终给予专业的健康和安全措施。在整个研究过程中，监测VEM是否受到标准护理的“污染”。

基线评估

基线评估包括年龄、性别、牛津郡卒中分型[17]、卒中严重程度(根据NIHSS确定)、糖尿病及其他卒中危险因素、卒中前的生活方式、卒中前功能分层(根据mRS确定)。应用急性卒中活动性评分(the mobility scale for acute stroke, MSAS)[18]来确定患者在床上的活动能力、坐起、行走10米等方面受限的情况，同时利用从该评分获得的信息来指导VEM干预措施的级别。

结局测量

分别在卒中后7天、14天、3个月、6个月及12个月时进行盲法评估。此次数据分析时，最感兴趣的结局指标是至能够行走50米的时间。其定义是患者第一次不需人为帮助而行走50米距卒中发病的天数，50米是功能独立性测量(FIM)中行走项目判定所用的距离[19]，而且常常在病房内划出50米的界限。为了降低与同时需要监督(FIM 5分)和助行器(FIM 6分)相关的主观性，我们将行走定义为“不需要人为帮助而能够连续行走50米(可以使用助步器)”。物理治疗师负责完成行走50米的测定。

其他的结局指标是卒中后3个月和24个月时的Barthel指数[5]和Rivermead运动功能评分[20]。Barthel指数是卒中研究中有效的、可靠的评价ADLs的指标[21,22]，它用来评价10项日常活动的独立性；总分是20分，分数越高，独立性越好。根据每次Barthel指数评分将患者分为ADLs独立组(20分)和非独立组(0-19分)。应用Rivermead运动功能评分来评价运动活动，它包含13个项目，其可靠性也已得
到证实。它同时包含容易的和困难的项目,第一个项目测试无支持时坐起的能力,其他项目测试转移、室内行走、室外行走、跑和原地跳跃的能力。进行三次测试,记录最好的一次,0 分表示患者不能独立完成任何一项活动,13 分提示患者能够独立完成所有活动。将患者分为运动活动受损组 (0-9 分) 和未受损组 (10-13 分),该分界点与有临床意义的户外行走能力一致。

统计分析

70 例的样本量,足够以本研究的主要安全性结局测量指标 (卒中后 3 个月时的死亡) 来检查本研究的安全性。虽然本研究探测不同躯体活动结局的效力不强,但是可进行可行性分析,评估结局测量指标的表现和应用效能。

因为在卒中后最初的 12 个月内,有 1/3 的患者死亡,所以分析时必须考虑到死亡造成的数据缺失。而且本研究入组标准宽,卒中症状会有显著的不同,造成一些病人在某项测试尤其是在与高级活动相关的测试中不能得任何分。除非有其他说明。TACI, 完全性前循环梗死; PACI, 部分前循环梗死; POCI, 后循环梗死; LACI, 腔隙性梗死; ICH, 脑出血。

至能行走的天数

记录卒中发病与独立行走 50 米之间的天数。对重要的影响预后的变量 (年龄、性别、NIHSS、卒中
36

前 mRS 和糖尿病) 进行校正后，进行 Cox 回归分析。

**Barthel 指数**

对 Barthel 指数进行 Mann-Whitney U 检验，评估其组间差异。根据 Barthel 指数将患者分为 ADLs 独立组和非独立组，进行 Fisher’s 确切概率检验评价组间差异。将 Barthel 指数作为二分类结局变量，对组别(VEM 组或 SC 组)、年龄、性别、NIHSS、卒中前 mRS、糖尿病进行多变量 logistic 回归分析，评价其对 ADLs 独立性的影响。

**Rivermead 运动功能评分**

对 Rivermead 运动功能评分进行 Mann-Whitney U 检验，分析其组间差异。根据 Rivermead 运动功能评分将患者分为运动活动受损组和未受损组，进行 Fisher’s 确切概率检验，评价组间差异。用与 Barthel 指数相同的方法，对 Rivermead 运动功能评分进行多变量 logistic 回归分析。

### 结果

2004 年至 2006 年共入组了 71 例患者：其中 60 例来自 Austin 医院、11 例来自 St. Vincent 医院（图 1）。不同组的基线特征相似（表 1）。值得注意的是，58% 的患者有中度或重度的卒中。VEM 组开始活动的中位时间比 SC 组短 (VEM 组 18 小时, SC 组 31 小时), VEM 组的中位总活动剂量比 SC 组大 (VEM 组 168 分钟, SC 组 69 分钟) [14]。3 个月时 11 例 (15%) 患者死亡，12 个月时 17 例 (24%) 死亡。两组间死亡比例无差异，且基于人群的研究死亡比例低 [14]。3 例存活者有数据缺失，但是分析其特征未发现任何系统偏倚。他们并非来自同一组 (2 例 VEM 组, 1 例 SC 组)，年龄分布也有一定范围 (58、82、86 岁)，卒中程度也不重 (NIHSS 分别为 1、5、7 分)。

至能行走的天数

入院时，86% 的患者不能行走或者需要搀扶才能短距离行走 (MSAS 步态评分 1-4 分, VEM 组 34 例, SC 组 27 例)。仅 14% 的患者能够在监督下行走 (VEM 组 4 例, SC 组 6 例)。VEM 组至能够行走 50 米所需的中位天数是 3.5 天 (四分位间距[IQR], 1.5-4), SC 组所需的中位天数是 7.0 天 (IQR, 2.0-20.0)。卒中后两周存活的患者中，67% 的 VEM 组患者能够独立行走，与之相比，50% 的 SC 组患者能够独立行走。校正了可能引起混淆的变量的 Cox 回归分析证实；干预措施对至能行走的天数有显著的影响 (P=0.032；表 2)。Log-minus-log 分析 (对数累积生

### 表 2 至能独立行走 50 米的天数的 Cox 回归分析 (N=71)

<table>
<thead>
<tr>
<th></th>
<th>危险比</th>
<th>95% CI</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>VEM</td>
<td>0.523</td>
<td>0.289</td>
<td>0.945</td>
</tr>
<tr>
<td>年龄</td>
<td>0.967</td>
<td>0.944</td>
<td>0.990</td>
</tr>
<tr>
<td>性别</td>
<td>0.679</td>
<td>0.374</td>
<td>1.233</td>
</tr>
<tr>
<td>NIHSS</td>
<td>0.864</td>
<td>0.815</td>
<td>0.916</td>
</tr>
<tr>
<td>发病前 mRS</td>
<td>0.867</td>
<td>0.645</td>
<td>1.165</td>
</tr>
<tr>
<td>糖尿病</td>
<td>2.147</td>
<td>1.020</td>
<td>4.520</td>
</tr>
</tbody>
</table>

### 表 3 多变量二元 Logistic 回归分析，以 3 个月和 12 个月时的 ADLs 独立性 (Barthel 指数 = 20 vs Barthel 指数 = 0-19) 作为结果变量

<table>
<thead>
<tr>
<th></th>
<th>OR</th>
<th>95% CI</th>
<th>P</th>
<th></th>
<th>OR</th>
<th>95% CI</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>VEM</td>
<td>11.24</td>
<td>1.88</td>
<td>67.31</td>
<td>0.008</td>
<td>4.19</td>
<td>0.46</td>
<td>37.84</td>
</tr>
<tr>
<td>年龄</td>
<td>0.85</td>
<td>0.75</td>
<td>0.95</td>
<td>0.005</td>
<td>0.74</td>
<td>0.60</td>
<td>0.91</td>
</tr>
<tr>
<td>性别</td>
<td>1.33</td>
<td>0.29</td>
<td>6.06</td>
<td>0.710</td>
<td>14.56</td>
<td>1.62</td>
<td>130.88</td>
</tr>
<tr>
<td>NIHSS</td>
<td>0.71</td>
<td>0.56</td>
<td>0.90</td>
<td>0.005</td>
<td>0.62</td>
<td>0.43</td>
<td>0.89</td>
</tr>
<tr>
<td>发病前 mRS</td>
<td>0.88</td>
<td>0.33</td>
<td>2.38</td>
<td>0.808</td>
<td>0.51</td>
<td>0.16</td>
<td>1.63</td>
</tr>
<tr>
<td>糖尿病</td>
<td>0.43</td>
<td>0.06</td>
<td>2.83</td>
<td>0.379</td>
<td>0.06</td>
<td>0.09</td>
<td>0.89</td>
</tr>
</tbody>
</table>

*包括了 11 例死亡患者，Barthel 指数定为 0 分；3 例存活者有数据缺失。
†包括了 17 例死亡患者，Barthel 指数定为 0 分；2 例存活者有数据缺失。
表 4 多变量二元 Logistic 回归分析。以 3 个月和 12 个月时的运动功能独立性 (Rivermead 运动功能评分 = 10-13 vs Rivermead 运动功能评分 =0-9) 作为结果变量

<table>
<thead>
<tr>
<th></th>
<th>3 个月 (N=68)*</th>
<th></th>
<th></th>
<th>12 个月 (N=69)†</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>OR</td>
<td>95% CI</td>
<td>P</td>
<td>OR</td>
<td>95% CI</td>
<td>P</td>
</tr>
<tr>
<td>VEM</td>
<td>8.21</td>
<td>1.00</td>
<td>67.64</td>
<td>0.50</td>
<td>9.62</td>
<td>1.34</td>
</tr>
<tr>
<td>年龄</td>
<td>0.90</td>
<td>0.81</td>
<td>1.00</td>
<td>0.046</td>
<td>0.88</td>
<td>0.78</td>
</tr>
<tr>
<td>性别</td>
<td>1.52</td>
<td>0.27</td>
<td>8.67</td>
<td>0.635</td>
<td>4.44</td>
<td>0.83</td>
</tr>
<tr>
<td>NIHSS</td>
<td>0.66</td>
<td>0.54</td>
<td>0.82</td>
<td>0.001</td>
<td>0.71</td>
<td>0.59</td>
</tr>
<tr>
<td>发病前</td>
<td>0.66</td>
<td>0.27</td>
<td>1.62</td>
<td>0.361</td>
<td>0.44</td>
<td>0.18</td>
</tr>
</tbody>
</table>

OR：比值比。
* 包括了 11 例死亡患者，Rivermead 运动功能评分定为 0 分；2 例存活者有数据缺失。
† 包括了 17 例死亡患者，Rivermead 运动功能评分定为 0 分；2 例存活者有数据缺失。

表 4 中数据未显示存活患者所得的结果相似，但是与年龄无明显相关 (数据未显示)。

讨论

本研究最重要的发现是同时接受超早期活动的患者比仅获得卒中单元护理的患者能够更快的恢复独立行走。此发现的主要临床意义是患者更快的恢复行走，增加了从急性治疗中直接出院回家而不需要去康复机构的可能性。我们的数据支持这种可能性：虽然 VEM 组较 SC 组有更多的中到重度卒中患者，但是 VEM 组患者在急性治疗医院中的时间比 SC 组短 (中位时间分别为 6 天和 7 天)，而且更多的 VEM 组患者直接出院回家 (32% vs 24%)。Indredavik 等 [13] 的研究显示短时间内的开始活动是影响出院回家的最重要的因素，也支持我们的观点。更快的恢复行走的可能原因是更早和更频繁的下床活动改善了运动机能；另一个可能的原因是，增加的躯体活动使肌肉萎缩最小化，增加了独立行走的可能。VEM 组与 SC 组在运动功能评分方面没有显著差异 (VEM 组中位得分为 10.0, IQR, 0.5-11.0; SC 组中位得分为 10.0, IQR, 3.0-11.0; P=0.883)。3 个月时，62%(23/37) 的 VEM 组患者获得了好的的 (根据 Rivermead 运动功能评分确定) 结局，56%(18/32) 的 SC 组患者获得了好的结局 (P=0.633)。12 个月时两组患者的运动功能评分无显著差异，53% 的 VEM 组患者获得了好的结局 (中位得分为 10.0, IQR, 0.0-11.0)，45% 的 SC 组患者获得了好的结局 (中位得分为 9.0, IQR, 1.0-11.0)。多元回归分析显示，3 个月与 9 个月时好的 Rivermead 运动功能评分结局均与 VEM、入组时较轻的卒中 (NIHSS)、年龄轻独立相关 (表 4)。只分析存活者所得的结果相似，但是与年龄无明显相关 (数据未显示)。

Barthel 指数

3 个月时 21% 的存活者由代理人回答问题，12 个月时 17% 由代理人回答 (主要是因为患者交流有困难)。Barthel 指数的分布呈双峰型，多数患者集中在最低分或最高分。3 个月时 VEM 组 Barthel 指数得分高于 SC 组 (VEM 组中位得分 18.5, IQR, 2.0-20.0; SC 组中位得分 16.5, IQR, 9.0-20.0)，但是差异没有统计学意义 (P=0.713)。3 个月时，47% 的 VEM 组患者获得了好的 (根据 Barthel 指数确定) 的结局，28% 的 SC 组患者获得了好的结局 (P=0.13)。12 个月时两组患者的 Barthel 指数得分无显著差异，VEM 组与 SC 组患者均有 39% 获得了好的结局 (VEM 组中位得分 18.0, IQR, 0.0-20.0; SC 组中位得分 18.0, IQR, 7.0-20.0)。多元回归分析显示，3 个月时好的 Barthel 指数结局与 VEM、入组时较轻的卒中 (NIHSS)、年龄轻独立相关。12 个月时好的 Barthel 指数结局与较轻的卒中、年龄轻、男性、无糖尿病独立相关，但是与 VEM 无明显相关 (表 3)。只分析存活患者所得的结果相似 (数据未显示)。

Rivermead 运动功能评分

VEM 组与 SC 组 3 个月时的 Rivermead 运动功能评分相似 (VEM 组中位得分 10.0, IQR, 0.5-11.0; SC 组中位得分为 10.0, IQR, 3.0-11.0; P=0.883)。3 个月时，62%(23/37) 的 VEM 组患者获得了好的的 (根据 Rivermead 运动功能评分确定) 结局，56%(18/32) 的 SC 组患者获得了好的结局 (P=0.633)。12 个月时两组患者的运动功能评分无显著差异，53% 的 VEM 组患者获得了好的结局 (中位得分为 10.0, IQR, 0.0-11.0)，45% 的 SC 组患者获得了好的结局 (中位得分为 9.0, IQR, 1.0-11.0)。多元回归分析显示，3 个月与 9 个月时好的 Rivermead 运动功能评分结局均与 VEM、入组时较轻的卒中 (NIHSS)、年龄轻独立相关 (表 4)。只分析存活者所得的结果相似，但是与年龄无明显相关 (数据未显示)。

Barthel 指数

3 个月时 21% 的存活者由代理人回答问题，12 个月时 17% 由代理人回答 (主要是因为患者交流有困难)。Barthel 指数的分布呈双峰型，多数患者集中在最低分或最高分。3 个月时 VEM 组 Barthel 指数得分高于 SC 组 (VEM 组中位得分 18.5, IQR, 2.0-20.0; SC 组中位得分 16.5, IQR, 9.0-20.0)，但是差异没有统计学意义 (P=0.713)。3 个月时，47% 的 VEM 组患者获得了好的 (根据 Barthel 指数确定) 的结局，28% 的 SC 组患者获得了好的结局 (P=0.13)。12 个月时两组患者的 Barthel 指数得分无显著差异，VEM 组与 SC 组患者均有 39% 获得了好的结局 (VEM 组中位得分 18.0, IQR, 0.0-20.0; SC 组中位得分 18.0, IQR, 7.0-20.0)。多元回归分析显示，3 个月时好的 Barthel 指数结局与 VEM、入组时较轻的卒中 (NIHSS)、年龄轻独立相关。12 个月时好的 Barthel 指数结局与较轻的卒中、年龄轻、男性、无糖尿病独立相关，但是与 VEM 无明显相关 (表 3)。只分析存活患者所得的结果相似 (数据未显示)。

Rivermead 运动功能评分

VEM 组与 SC 组 3 个月时的 Rivermead 运动功能评分相似 (VEM 组中位得分 10.0, IQR, 0.5-11.0; SC 组中位得分为 10.0, IQR, 3.0-11.0; P=0.883)。3 个月时，62%(23/37) 的 VEM 组患者获得了好的的 (根据 Rivermead 运动功能评分确定) 结局，56%(18/32) 的 SC 组患者获得了好的结局 (P=0.633)。12 个月时两组患者的运动功能评分无显著差异，53% 的 VEM 组患者获得了好的结局 (中位得分为 10.0, IQR, 0.0-11.0)，45% 的 SC 组患者获得了好的结局 (中位得分为 9.0, IQR, 1.0-11.0)。多元回归分析显示，3 个月与 9 个月时好的 Rivermead 运动功能评分结局均与 VEM、入组时较轻的卒中 (NIHSS)、年龄轻独立相关 (表 4)。只分析存活者所得的结果相似，但是与年龄无明显相关 (数据未显示)。
等级的功能 [3]。应该注意的是，我们的研究探测早期活动所致的功能结局变化的效力不强。如表 3、4 所示，干预措施的效果的置信区间较宽，需要在更大规模的 III 期研究（正在进行中）[28]进一步确定这些发现。

年龄和卒中严重程度对 3 个月和 6 个月时的卒中结局（根据 Barthel 指数和 Rivermead 运动功能评分确定）有很强的影响，年轻患者和卒中程度轻的患者将获得更大的功能独立性。该发现与既往研究结果一致 [7-9]。既往也有研究显示糖尿病对行走恢复及 12 个月时的 Barthel 指数有负面的影响 [8,10]。

Barthel 指数和 Rivermead 运动功能评分并不是完美的研究结局测量指标。它们是简短的等级评分，评分结果不呈正态分布，而且 Barthel 指数有天花板效应。可能 12 个月时两组患者在 ADLs 独立性上有差异，而 Barthel 指数的天花板效应影响了这些差异的探测。12 个月时，超过一半的存活者达到了 Barthel 指数评分的天花板（即获得了满分 20 分）。Barthel 指数在区分有中等和高水平功能的患者上的劣势已得到充分证实 [29]。另外，Barthel 指数和 Rivermead 运动功能评分都没有包含死亡的情况（而 mRS 包含了死亡）。与许多发表的康复研究相比，本研究分析躯体活动结局时并未排除死亡。而为了避免高估死亡患者的恢复，我们将死亡者的这两项评分结果进行二分法分析，以免违反统计假设。二分法的后果是降低了测量的敏感性。但是这种策略在康复领域（无论是临床实践还是研究中）被广泛应用且欣然接受，所以我们选择了这种结局测量方法。

任何能加速卒中后功能恢复的措施对卒中患者和医生都很重要。本研究提供了新的证据：在卒中急性期，更早和更密集的活动可以加速行走功能独立性的恢复。AVERT III 的发现将更确定 VEM 对卒中后躯体独立性恢复的效力。

参考文献


